Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic – Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a…
Eli Lilly’s Orforglipron Data Is Not Disastrous: Analyst – Eli Lilly (NYSE:LLY)
Eli Lilly and Co LLY released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational…